Evidence map›Paper›PMID 38931398›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Exploring the Underlying Mechanisms of Qingxing Granules Treating H1N1 Influenza Based on Network Pharmacology and Experimental Validation.

Hujun Du, Lianying Zhang, Haoxiang Sun, Shaoqin Zheng, Hongying Zhang, Shijia Yuan, Jiuyao Zhou, Zihao Fang, Jianping Song, Manxue Mei and 1 more

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Network-Based Identification ofCurrent pharmaceutical design · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hujun DuArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Lianying ZhangArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Haoxiang SunArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Shaoqin ZhengSci-Tech Industrial Park, Guangzhou University of Chinese Medicine, Guangzhou 510330, China.
Hongying ZhangArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Shijia YuanArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Jiuyao ZhouDepartment of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510330, China.ORCID 0000-0003-3477-3370
Zihao FangThe Eighth Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Jianping SongArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Manxue MeiDepartment of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510330, China.ORCID 0000-0002-2831-9203
Changsheng DengArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.

Funding

Changsheng Deng 82374315Jianping Song 0730-236132ZC0052/03-2Jianping Song 2023A1111020001
6 · The paper itself

Abstract

backgroundH1N1 is one of the major subtypes of influenza A virus (IAV) that causes seasonal influenza, posing a serious threat to human health. A traditional Chinese medicine combination called Qingxing granules (QX) is utilized clinically to treat epidemic influenza. However, its chemical components are complex, and the potential pharmacological mechanisms are still unknown.

methodsQX's effective components were gathered from the TCMSP database based on two criteria: drug-likeness (DL ≥ 0.18) and oral bioavailability (OB ≥ 30%). SwissADME was used to predict potential targets of effective components, and Cytoscape was used to create a "Herb-Component-Target" network for QX. In addition, targets associated with H1N1 were gathered from the databases GeneCards, OMIM, and GEO. Targets associated with autophagy were retrieved from the KEGG, HAMdb, and HADb databases. Intersection targets for QX, H1N1 influenza, and autophagy were identified using Venn diagrams. Afterward, key targets were screened using Cytoscape's protein-protein interaction networks built using the database STRING. Biological functions and signaling pathways of overlapping targets were observed through GO analysis and KEGG enrichment analysis. The main chemical components of QX were determined by high-performance liquid chromatography (HPLC), followed by molecular docking. Finally, the mechanism of QX in treating H1N1 was validated through animal experiments.

resultsA total of 786 potential targets and 91 effective components of QX were identified. There were 5420 targets related to H1N1 and 821 autophagy-related targets. The intersection of all targets of QX, H1N1, and autophagy yielded 75 intersecting targets. Ultimately, 10 core targets were selected: BCL2, CASP3, NFKB1, MTOR, JUN, TNF, HSP90AA1, EGFR, HIF1A, and MAPK3. Identification of the main chemical components of QX by HPLC resulted in the separation of seven marker ingredients within 195 min, which are amygdalin, puerarin, baicalin, phillyrin, wogonoside, baicalein, and wogonin. Molecular docking results showed that BCL2, CASP3, NFKB1, and MTOR could bind well with the compounds. In animal studies, QX reduced the degenerative alterations in the lung tissue of H1N1-infected mice by upregulating the expression of p-mTOR/mTOR and p62 and downregulating the expression of LC3, which inhibited autophagy.

conclusionsAccording to this study's network pharmacology analysis and experimental confirmation, QX may be able to treat H1N1 infection by regulating autophagy, lowering the expression of LC3, and increasing the expression of p62 and p-mTOR/mTOR.

Indexed as

autophagyH1N1HPLCinfluenza A virusmolecular dockingnetwork pharmacologyQingxing granules

Identifiers

PMID38931398
PMCPMC11206762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.